Athira Pharma to Participate in Upcoming June Conferences

BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences:

Jefferies Healthcare Conference
Fireside Chat on Wednesday, June 7, 2023, at 8:30 a.m. ET in New York

Goldman Sachs 44^th Annual Global Healthcare Conference
Presentation on Wednesday, June 14, 2023, at 8:40 a.m.PT in Dana Point, California

Live webcasts of the Jefferies fireside chat and Goldman Sachs presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies and amyotrophic lateral sclerosis (ALS). For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn, Twitter and @athirapharma on Instagram.

Investor & Media Contact:

Julie Rathbun
Athira Pharma
[email protected]
206-769-9219

You May Also Be Interested In

• Keystone Substance Abuse Services Rebrands as Keystone Behavioral Health, Expanding Behavioral Health Services in York County
• K-EnterTech Shines on the Global Stage! BIGC Wins Four Awards, Including the Stevie Awards and Good Design Awards
• What The Washington Post and Mark Robichaux Got Wrong About Menhaden